SCHEMBL8865472

SCHEMBL8865472

OC(c1cocn1)c1cocn1

nearest known ligand 0.33

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PLA2G7 Q13093 1/20 0.33
MGLL Q99685 1/20 0.33
ABHD6 Q9BV23 1/20 0.33
KAT7 O95251 2/20 0.32
KAT6A Q92794 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8630495 0.81 SMN1; SMN2 (0.40) KAT7KAT6A
SCHEMBL19267264 0.80
SCHEMBL28478255 0.75 GAA (0.44) KAT7KAT6A
SCHEMBL4293363 0.75
SCHEMBL30601568 0.74 CES2 (0.39) PLA2G7MGLLABHD6KAT7KAT6A
SCHEMBL13733688 0.74 SMN1; SMN2 (0.54)
SCHEMBL31098014 0.74 SMN1; SMN2 (0.54)
SCHEMBL29348975 0.74 ALDH1A1 (0.41) KAT7KAT6A
SCHEMBL15100903 0.74 PLA2G7 (0.30) PLA2G7MGLLABHD6
SCHEMBL17162314 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018004-B2 Carbamate compounds and methods of making and using same H. LUNDBECK A/S (DK) 2024-06-25 US disclosed
US-20230312499-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2023-10-05 US disclosed
US-20230312499-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2023-10-05 US disclosed
US-20230312499-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2023-10-05 US disclosed
US-11530189-B2 Carbamate compounds and methods of making and using same H. LUNDBECKA/S (DK) 2022-12-20 US disclosed
US-11530189-B2 Carbamate compounds and methods of making and using same H. LUNDBECKA/S (DK) 2022-12-20 US disclosed
CN-107982266-B Carbamate compounds and methods of making and using the same H.隆德贝克有限公司 2021-07-30 CN disclosed
US-20210188793-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME LUNDBECK LA JOLLA RESEARCH CENTER, INC. 2021-06-24 US disclosed
US-20210188793-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME LUNDBECK LA JOLLA RESEARCH CENTER, INC. 2021-06-24 US disclosed
US-11021453-B2 Carbamate compounds and methods of making and using same LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2021-06-01 US disclosed
WO-2013142307-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME ABIDE THERAPEUTICS (US) 2013-09-26 WO disclosed
WO-2013142307-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME ABIDE THERAPEUTICS (US) 2013-09-26 WO disclosed
WO-2013103973-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME ABIDE THERAPEUTICS (US) 2013-07-11 WO disclosed
WO-2013103973-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME ABIDE THERAPEUTICS (US) 2013-07-11 WO disclosed
US-5631264-A NEUROLOGICAL DISORDERS SANOFI WINTHROP, INC. (US) 1997-05-20 US disclosed
US-5604224-A NEURODEGENERATIVE DISORDERS STERLING WINTHROP INC. (US) 1997-02-18 US disclosed
US-5569655-A Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof STERLING WINTHROP INC. (US) 1996-10-29 US disclosed
US-5554620-A Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof STERLING WINTHROP INC. (US) 1996-09-10 US disclosed
EP-0656359-A1 Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts and compositionsand methods of use thereof STERLING WINTHROP INC. (US) 1995-06-07 EP disclosed
EP-0647641-A1 Substituted heterocyclylisoquinolinium salts and compositions and methods of usethereof STERLING WINTHROP INC. (US) 1995-04-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11530189-B2 Carbamate compounds and methods of making and using same ABHD6, ABHD16A, RABL6 PLA2G7 195/4885MGLL 54/4885ABHD6 1/4885
US-11021453-B2 Carbamate compounds and methods of making and using same ABHD6, ABHD16A, RABL6 PLA2G7 223/4885MGLL 60/4885ABHD6 1/4885
US-20210188793-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME ABHD6, ABHD16A, RABL6 PLA2G7 195/4885MGLL 54/4885ABHD6 1/4885
US-20230312499-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME ABHD6, ABHD16A, RABL6 PLA2G7 195/4885MGLL 54/4885ABHD6 1/4885
US-12018004-B2 Carbamate compounds and methods of making and using same ABHD6, ABHD16A, RABL6 PLA2G7 195/4885MGLL 54/4885ABHD6 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.